Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray

Cancer Science

Volumn 95, Issue 3, 2004, Pages 218-225

  Nagahata, Takemitsu ^a,b   Onda, Masamitsu ^a   Emi, Mitsuru ^a   Nagai, Hisaki ^a   Tsumagari, Koji ^a   Fujimoto, Takashi ^a   Hirano, Akira ^a   Sato, Takamichi ^b   Nishikawa, Kiyohiro ^b   Akiyama, Futoshi ^c   Sakamoto, Goi ^c   Kasumi, Fujio ^c   Miki, Yoshio ^c   Tanaka, Toshihiro ^a,d   Tsunoda, Tatsuhiko ^a,d  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; MOLECULAR MARKER; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEOTIDE SEQUENCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE PERIOD; PROGNOSIS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 11144357671     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb02206.x     Document Type: Article

References (39)

1. Goldhirsch A, Glick J, Gelber R, Coates A, Senn H. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-27.
2. Abrams JS. Adjuvant therapy for breast cancer-results from the USA consensus conference. Breast Cancer 2001; 8: 298-304.
3. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83: 154-5.
4. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-89.
5. Peron CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Burstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-7.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
7. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462-7.
8. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 5979-84.
9. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, Mackay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB, Sager R. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 2000; 60: 2232-8.
10. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001; 61: 5168-78.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
12. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
13. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756-61.
14. Harris J, Henderson I. Staging and prognostic factors. In: Harris J, editor. Breast diseases. Philadelphia: Lippincott; 1987. p. 327-46.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
16. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987; 1: 423-30.
17. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-7.
18. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: 137-43.
19. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992; 28: 697-700.
20. Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest AP, Evans HJ. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990; 61: 74-8.
21. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26: 225-35.
22. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 1994; 54: 499-505.
23. Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992; 339: 139-43.
24. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
25. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-5.
26. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM, Polymeropoulos MH. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003; 63: 2194-9.
27. Unger MA, Rishi M, Clemmer VB, Hartman JL, Keiper EA, Greshock JD, Chodosh LA, Liebman MN, Weber BL. Characterization of adjacent breast tumors using oligonucleotide microarrays. Breast Cancer Res 2001; 3: 336-41.
28. Assersohn L, Gangi L, Zhao Y, Dowsett M, Simon R, Powles TJ, Liu ET. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 2002; 8: 794-801.
29. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359: 131-2.
30. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
31. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 1996; 2: 1199-206.
32. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6.
33. Polette M, Clavel C, Cockett M, Girod de Bentzmann S, Murphy G, Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993; 13: 31-7.
34. Yanagisawa J, Kitagawa H, Yanagida M, Wada O, Ogawa S, Nakagomi M, Oishi H, Yamamoto Y, Nagasawa H, McMahon SB, Cole MD, Tora L, Takahashi N, Kato S. Nuclear receptor function requires a TFTC-type histone acetyl transferase complex. Mol Cell 2002; 9: 553-62.
35. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of NMA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci USA 2002; 99: 3836-41.
36. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001; 165: 1-10.
37. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80: 239-56.
38. Emi M, Yoshimoto M, Sato T, Matsumoto S, Utada Y, Ito I, Minobe K, Iwase T, Katagiri T, Bando K, Akiyama F, Harada Y, Fukino K, Sakamoto G, Matsushima M, Iida A, Tada T, Saito H, Miki Y, Kasumi F, Nakamura Y. Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor post-operative prognosis in breast cancer. Genes Chromosom Cancer 1999; 26: 134-41.
39. Utada Y, Emi M, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res 2000; 6: 3193-8.